Immunocore
IMCR
IMCR
86 hedge funds and large institutions have $1.25B invested in Immunocore in 2022 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
12.34% more ownership
Funds ownership: 47.97% → 60.31% (+12%)
86% less call options, than puts
Call options by funds: $1.39M | Put options by funds: $9.91M
Holders
86
Holding in Top 10
6
Calls
$1.39M
Puts
$9.91M
Top Buyers
| 1 | +$47.5M | |
| 2 | +$39.9M | |
| 3 | +$38.6M | |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$34.2M |
| 5 |
Holocene Advisors
New York
|
+$23.5M |
Top Sellers
| 1 | -$27.7M | |
| 2 | -$9.3M | |
| 3 | -$7.49M | |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$3.75M |
| 5 |
PC
Pier Capital
Stamford,
Connecticut
|
-$2.52M |